Pharma Supply Chain Disruptions Affect Consumer Patient Care

Supply chain disruptions have been wide spread throughout the pharmaceutical and medical fields. But unfortunately according to doctors, we now know that there are real affects for patients.

Karanov Images Stock adobe com

It is not breaking news to say that there are numerous supply chain disruptions in the medical industry throughout the pandemic. But some can wonder if there are real effects coming from these disruptions on the patient care side of things? According to a new survey from U.S. Pharmacopeia, 95% of physicians in the United States say that the Coronavirus (COVID-19) revealed vulnerabilities that are likely not to dissipate after the pandemic subsides. Ninety percent of those surveyed are worried that the supply of global medicines are not reliable in a time of crisis and 83% say drug shortages have become a significant problem in recent years. 

Per PR Newswire

  • Physicians working in underserved communities were more likely to report negative outcomes from medication shortages than physicians who do not serve those vulnerable communities (37% vs. 29% reported negative outcomes "often" or "sometimes" from such shortages), and physicians working in underserved communities were more likely to recommend non-drug alternatives when shortages occurred during the previous 18 months (32% vs. 23%).2 Misinformation on the internet, social media, and the news also makes it more difficult to treat patients, according to 94% of survey respondents.
  • Most physicians surveyed (62%) believe significant reliance on other countries for medicines is among the biggest contributing factors to possible medicine shortages. More than four out of five (83%) believe the U.S. is too dependent on medicines manufactured in other countries, and 90% say more medicines need to be produced in the U.S.

"As Congress considers bipartisan legislation on pandemic preparedness, the survey results further strengthen the case to meaningfully address medicines supply chain vulnerabilities, including the potential for drug shortages, before the next public health crisis," says Ronald T. Piervincenzi, Ph.D., CEO of U.S. Pharmacopeia. "Despite its enormous complexity the medicines supply chain has not 'broken.' Rather, the pandemic surfaced both longstanding vulnerabilities and acute, pandemic-driven resiliency gaps," Piervincenzi continued. "We must continue to work together on multi-pronged solutions to identify and mitigate supply chain vulnerabilities that adversely impact physicians' ability to deliver quality care and erode trust in quality medicines."